Elsevier

Neurobiology of Aging

Volume 29, Issue 11, November 2008, Pages 1619-1630
Neurobiology of Aging

Loss of VGLUT1 and VGLUT2 in the prefrontal cortex is correlated with cognitive decline in Alzheimer disease

https://doi.org/10.1016/j.neurobiolaging.2007.04.010Get rights and content

Abstract

Several lines of evidence suggest that the glutamatergic system is severely impaired in Alzheimer disease (AD). Here, we assessed the status of glutamatergic terminals in AD using the first available specific markers, the vesicular glutamate transporters VGLUT1 and VGLUT2. We quantified VGLUT1 and VGLUT2 in the prefrontal dorsolateral cortex (Brodmann area 9) of controls and AD patients using specific antiserums. A dramatic decrease in VGLUT1 and VGLUT2 was observed in AD using Western blot. Similar decreases were observed in an independent group of subjects using immunoautoradiography. The VGLUT1 reduction was highly correlated with the degree of cognitive impairment, assessed with the clinical dementia rating (CDR) score. A significant albeit weaker correlation was also observed with VGLUT2. These findings provide evidence indicating that glutamatergic systems are severely impaired in the A9 region of AD patients and that this impairment is strongly correlated with the progression of cognitive decline. Our results suggest that VGLUT1 expression in the prefrontal cortex could be used as a valuable neurochemical marker of dementia in AD.

Introduction

Alzheimer disease (AD) is the major and most severe form of dementia in the elderly. Synaptic loss, together with cholinergic deficits, intraneuronal neurofibrillary tangles and extracellular beta-amyloid (Aβ) peptide deposits, are considered the landmarks of AD (Braak and Braak, 1991, DeKosky and Scheff, 1990). Numerous observations have also accumulated suggesting a glutamatergic deficit in the pathophysiologic mechanisms underlying AD (Francis, 2003). Glutamate is the major excitatory neurotransmitter of the brain; in particular, it is the main neurotransmitter of cortical and hippocampal pyramidal neurons and is thus involved in higher mental functions such as cognition, learning and memory. In AD, tau protein hyperphosphorylation, which leads to neurofibrillary tangle formation and amyloid precursor protein conversion to Aβ, occurs mainly in glutamatergic pyramidal cells (Lewis et al., 1987). Consequently, AD is associated with a selective loss of pyramidal neurons and their synapses in the cerebral cortex, leading to cortical atrophy (DeKosky and Scheff, 1990, Francis, 2003, Morrison and Hof, 2002, Pearson et al., 1985). The level of cognitive impairment in AD correlates more strongly with the loss of cortical pyramidal cells than with counts of neurofibrillary tangles or senile plaques or with the level of cholinergic markers in the cerebral cortex (Masliah et al., 1993, Neary et al., 1986, Terry et al., 1991).

In addition to these histopathological findings, numerous biochemical studies also support the notion of altered glutamatergic transmission in AD (Bell et al., 2006, Francis, 2003). The disease is associated with decreased concentration of glutamate in vivo (Antuono et al., 2001, Hattori et al., 2002) as well as in post-mortem brain tissue (Arai et al., 1985). Likewise, glutamate transport both at the plasma membrane and in synaptic vesicles is reduced in the cerebral cortex of AD patients (Hardy et al., 1987, Westphalen et al., 2003). Moreover, the glutamate transporter EAAT1, which is normally found in astrocytes, is atypically expressed by degenerating pyramidal cells in the cortex of AD patients (Scott et al., 2002).

Until recently, research on glutamatergic neurons was hindered by the lack of specific markers. Lately, three vesicular glutamate transporters (VGLUT1-3) have been identified (Fremeau et al., 2004a). These proton-dependent transporters upload glutamate into synaptic vesicles, and despite their distinct and complementary distribution in the central nervous system, share similar biochemical and pharmacologic characteristics (Fremeau et al., 2004a). Vesicular glutamate transporters confer to neurons the capacity to exocytotically release glutamate, and are the first available specific markers of glutamatergic neurons. In the human neocortex, pyramidal neurons express VGLUT1 mRNA in all layers, whereas VGLUT2 transcripts are expressed only in layers II and III (McCullumsmith and Meador-Woodruff, 2003). Thus, both VGLUT1 and VGLUT2-positive terminals account for the flow of information in higher cognitive functions. In contrast, thalamo-cortical terminals, which represent the main sensory afference to the cerebral cortex, express only VGLUT2 (Fujiyama et al., 2001).

In the current study we analyzed VGLUT1 and VGLUT2 expression in the prefrontal cortex of AD patients and controls using subtype specific antiserums. We also examined whether VGLUT1 and VGLUT2 levels were correlated with cognitive deterioration, as assessed by the clinical dementia rating (CDR) scale.

Section snippets

Human brain samples

Brain samples were obtained from 17 patients and 11 controls from the geriatric department of the Emile Rous Hospital at Limeil-Brévannes, France (Table 1) (Delacourte et al., 1999, Grouselle et al., 1998). Subjects underwent a neuropsychological assessment every 6 months with the Mini-Mental State Examination (Folstein et al., 1975) and the clinical dementia rating (CDR) scale (Hughes et al., 1982) to evaluate their cognitive status. The CDR scores are as follows: 0 = no dementia, 0.5 = 

Immunoautoradiography

VGLUT1 and VGLUT2 were first analyzed by immunoautoradiography in the prefrontal cortex (A9) of five matched controls and patients. In both controls and patients, VGLUT1-positive terminals appeared to be homogeneously distributed in the cortex, in agreement with previous studies (Fig. 1 and Alonso-Nanclares and Defelipe, 2005). For the first time, we report the immunodistribution of VGLUT2 in the human cerebral cortex (Fig. 1). Unlike what is seen in rodents (Kaneko et al., 2002), VGLUT2 was

VGLUT1 and VGLUT2 are severely decreased in the prefrontal cortex of AD patients

In the present study, we quantified VGLUT1 and VGLUT2 immunodistribution in the A9 region of the prefrontal cortex from controls and AD patients. Using three different methods (Western blot, immunoautoradiography and immunohistochemistry) we showed a dramatic decline of both vesicular glutamate transporters in the prefrontal cortex of AD patients.

AD is characterized by a progressive and severe decline of cognitive functions whereas sensory-motor functions are affected only at late stages of the

Disclosure statement

The authors declare that they have no actual or potential conflicts of interest.

Acknowledgments

This work was supported by grants from Institut National de la Santé et de la Recherche Médicale (INSERM), Fédération pour la Recherche sur le Cerveau (FRC) and Association France Parkinson. AK and EL were supported by a fellowship from Association France Alzheimer. The authors wish to thank the families who generously donated the brain samples for the present research program.

References (59)

  • E. Herzog et al.

    Localization of VGLUT3, the vesicular glutamate transporter type 3, in the rat brain

    Neuroscience

    (2004)
  • A. Kashani et al.

    Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease

    Neurobiol. Aging

    (2007)
  • A. Levey et al.

    Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease

    Clin. Ther.

    (2006)
  • G. Liu et al.

    Variability of neurotransmitter concentration and nonsaturation of postsynaptic AMPA receptors at synapses in hippocampal cultures and slices

    Neuron

    (1999)
  • E. Masliah et al.

    The synaptic organization of the neocortex in Alzheimer's disease

    Med. Hypotheses

    (1993)
  • E. Masliah et al.

    Synaptic and neuritic alterations during the progression of Alzheimer's disease

    Neurosci. Lett.

    (1994)
  • J.H. Morrison et al.

    Selective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer's disease

    Prog. Brain Res.

    (2002)
  • B. Permanne et al.

    Quantitation of Alzheimer's amyloid peptide and identification of related amyloid proteins by dot-blot immunoassay

    Brain Res.

    (1995)
  • S. Shimohama et al.

    Differential involvement of synaptic vesicle and presynaptic plasma membrane proteins in Alzheimer's disease

    Biochem. Biophys. Res. Commun.

    (1997)
  • C.I. Sze et al.

    Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer's disease brains

    J. Neurol. Sci.

    (2000)
  • J. Williams

    How does a vesicle know it is full?

    Neuron

    (1997)
  • P.G. Antuono et al.

    Decreased glutamate + glutamine in Alzheimer's disease detected in vivo with (1)H-MRS at 0.5 T

    Neurology

    (2001)
  • H. Braak et al.

    Neuropathological stageing of Alzheimer-related changes

    Acta Neuropathol. (Berl.)

    (1991)
  • T. Bussiere et al.

    Progressive degeneration of nonphosphorylated neurofilament protein-enriched pyramidal neurons predicts cognitive impairment in Alzheimer's disease: stereologic analysis of prefrontal cortex area 9

    J. Comp. Neurol.

    (2003)
  • P. Davies et al.

    Recent advances in the neurochemistry of Alzheimer's disease

    J. Clin. Psychiat.

    (1987)
  • S. De Gois et al.

    Homeostatic scaling of vesicular glutamate and GABA transporter expression in rat neocortical circuits

    J. Neurosci.

    (2005)
  • S.T. DeKosky et al.

    Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity

    Ann. Neurol.

    (1990)
  • A. Delacourte et al.

    The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease

    Neurology

    (1999)
  • V. Deramecourt et al.

    Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies

    J. Neuropathol. Exp. Neurol.

    (2006)
  • Cited by (135)

    • HEBP1 - An early trigger for neuronal cell death and circuit dysfunction in Alzheimer's disease

      2023, Seminars in Cell and Developmental Biology
      Citation Excerpt :

      The association was initially described through two independent methods, the estimation of synapse number using microscopic techniques [15] and the measurements of synaptic protein concentrations [16], each of which showed a strong correlation between synapse number (or synaptic proteins) and cognition scores on the Mini-Mental Status Examination (MMSE). These findings have been replicated using a variety of approaches [17–25], including disease models. Furthermore, position emission tomography imaging with radiolabelled fluorodeoxyglucose (FDG) and, more recently, functional magnetic resonance imaging (fMRI) of AD patients demonstrated reductions in neuronal activities in these patients and uncovered connectivity changes between different brain regions that correlated with AD pathology, in lined with the progressive decline in learning and memory [26].

    • Chronic oral d-galactose intake provokes age-related changes in the rat prefrontal cortex

      2023, Behavioural Brain Research
      Citation Excerpt :

      Development of cognitive impairments could be caused by altered synaptic transmission, where proteins involved in exocytosis such as vGlut1 and syntaxin-1 play a critical role. It is known that reduced vGlut1 has been highly correlated with the degree of cognitive impairment in humans [25]. Herein, we report significantly decreased levels of both vGlut1 and syntaxin-1, suggesting jeopardized glutamate import into synaptic vesicles and vesicle fusion, which may result in diminished glutamate content in the synaptic cleft.

    View all citing articles on Scopus
    View full text